Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Background: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers.

Methods: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort.